Cargando…

Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies

Since its discovery in 1976, Ebolavirus has caused periodic outbreaks of viral hemorrhagic fever associated with severe and often fatal disease. Ebolavirus is endemic in Central Africa and the Philippines. Although there is currently no approved treatment available, the past 10 years has seen remark...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, Emmie, Feldmann, Heinz, Munster, Vincent J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092090/
https://www.ncbi.nlm.nih.gov/pubmed/21349211
http://dx.doi.org/10.1186/gm219
_version_ 1782203350345842688
author de Wit, Emmie
Feldmann, Heinz
Munster, Vincent J
author_facet de Wit, Emmie
Feldmann, Heinz
Munster, Vincent J
author_sort de Wit, Emmie
collection PubMed
description Since its discovery in 1976, Ebolavirus has caused periodic outbreaks of viral hemorrhagic fever associated with severe and often fatal disease. Ebolavirus is endemic in Central Africa and the Philippines. Although there is currently no approved treatment available, the past 10 years has seen remarkable progress in our understanding of the pathogenicity of Ebolavirus and the development of prophylactic and post-exposure therapies against it. In vitro and in vivo experiments have shown that Ebolavirus pathogenicity is multifactorial, including viral and host determinants. Besides their function in the virus replication cycle, the viral glycoprotein, nucleoprotein, minor matrix protein and polymerase cofactor are viral determinants of pathogenicity, with evasion of the host innate and adaptive immune responses as the main mechanism. Although no licensed Ebolavirus vaccines are currently available, vaccine research in non-human primates, the 'gold standard' animal model for Ebolavirus, has produced several promising candidates. A combination of DNA vaccination and a recombinant adenovirus serotype 5 boost resulted in cross-protective immunity in non-human primates. A recombinant vesicular stomatitis vaccine vector protected non-human primates in pre- and post-exposure challenge studies. Several antiviral therapies are currently under investigation, but only a few of these have been tested in non-human primate models. Antisense therapies, in which oligonucleotides inhibit viral replication, have shown promising results in non-human primates following post-exposure treatment. In light of the severity of Ebolavirus disease and the observed increase in Ebolavirus outbreaks over the past decade, the expedited translation of potential candidate therapeutics and vaccines from bench to bedside is currently the most challenging task for the field. Here, we review the current state of Ebolavirus research, with emphasis on prophylactic and therapeutic intervention strategies.
format Text
id pubmed-3092090
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30920902012-01-27 Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies de Wit, Emmie Feldmann, Heinz Munster, Vincent J Genome Med Review Since its discovery in 1976, Ebolavirus has caused periodic outbreaks of viral hemorrhagic fever associated with severe and often fatal disease. Ebolavirus is endemic in Central Africa and the Philippines. Although there is currently no approved treatment available, the past 10 years has seen remarkable progress in our understanding of the pathogenicity of Ebolavirus and the development of prophylactic and post-exposure therapies against it. In vitro and in vivo experiments have shown that Ebolavirus pathogenicity is multifactorial, including viral and host determinants. Besides their function in the virus replication cycle, the viral glycoprotein, nucleoprotein, minor matrix protein and polymerase cofactor are viral determinants of pathogenicity, with evasion of the host innate and adaptive immune responses as the main mechanism. Although no licensed Ebolavirus vaccines are currently available, vaccine research in non-human primates, the 'gold standard' animal model for Ebolavirus, has produced several promising candidates. A combination of DNA vaccination and a recombinant adenovirus serotype 5 boost resulted in cross-protective immunity in non-human primates. A recombinant vesicular stomatitis vaccine vector protected non-human primates in pre- and post-exposure challenge studies. Several antiviral therapies are currently under investigation, but only a few of these have been tested in non-human primate models. Antisense therapies, in which oligonucleotides inhibit viral replication, have shown promising results in non-human primates following post-exposure treatment. In light of the severity of Ebolavirus disease and the observed increase in Ebolavirus outbreaks over the past decade, the expedited translation of potential candidate therapeutics and vaccines from bench to bedside is currently the most challenging task for the field. Here, we review the current state of Ebolavirus research, with emphasis on prophylactic and therapeutic intervention strategies. BioMed Central 2011-01-27 /pmc/articles/PMC3092090/ /pubmed/21349211 http://dx.doi.org/10.1186/gm219 Text en Copyright ©2011 BioMed Central Ltd
spellingShingle Review
de Wit, Emmie
Feldmann, Heinz
Munster, Vincent J
Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title_full Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title_fullStr Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title_full_unstemmed Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title_short Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
title_sort tackling ebola: new insights into prophylactic and therapeutic intervention strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092090/
https://www.ncbi.nlm.nih.gov/pubmed/21349211
http://dx.doi.org/10.1186/gm219
work_keys_str_mv AT dewitemmie tacklingebolanewinsightsintoprophylacticandtherapeuticinterventionstrategies
AT feldmannheinz tacklingebolanewinsightsintoprophylacticandtherapeuticinterventionstrategies
AT munstervincentj tacklingebolanewinsightsintoprophylacticandtherapeuticinterventionstrategies